Received Nov 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PPV | PNEUMO (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | OT |
vaccine/ PPSV - 23 intravenously, which they indicated was administered incorrectly; This spontaneous report was received from a Consumer or other non health professional on 20-Oct-2025, referring to a male patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) intravenously, (lot # and expiration date were not reported) as prophylaxis. The caller expressed concerns about receiving the vaccine intravenously, which they indicated was administered incorrectly (Incorrect route of product administration). They inquired about potential long-term effects. The patient did not feel better after having the vaccine.